

Mihály Jászsi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5038774/publications.pdf>

Version: 2024-02-01

92
papers

6,131
citations

70961

41
h-index

71532

76
g-index

99
all docs

99
docs citations

99
times ranked

4014
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. <i>Blood</i> , 2008, 111, 1512-1514.	0.6	332
2	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. <i>Journal of Clinical Investigation</i> , 2003, 111, 1181-1190.	3.9	315
3	Deletion of Complement Factor H-Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome. <i>PLoS Genetics</i> , 2007, 3, e41.	1.5	285
4	Factor H family proteins and human diseases. <i>Trends in Immunology</i> , 2008, 29, 380-387.	2.9	230
5	C3 glomerulopathy – understanding a rare complement-driven renal disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 129-143.	4.1	223
6	Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. <i>Blood</i> , 2007, 110, 1516-1518.	0.6	222
7	Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. <i>Molecular Immunology</i> , 2006, 43, 97-106.	1.0	205
8	Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). <i>Journal of Medical Genetics</i> , 2005, 43, 582-589.	1.5	197
9	Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). <i>Kidney International</i> , 2006, 70, 42-50.	2.6	180
10	The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. <i>Clinical and Experimental Immunology</i> , 2006, 144, 342-352.	1.1	147
11	Leptospiral Immunoglobulin-like Proteins Interact With Human Complement Regulators Factor H, FHL-1, FHR-1, and C4BP. <i>Journal of Infectious Diseases</i> , 2012, 205, 995-1004.	1.9	132
12	Factor H-related proteins determine complement-activating surfaces. <i>Trends in Immunology</i> , 2015, 36, 374-384.	2.9	130
13	Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. <i>Cell Death and Differentiation</i> , 2009, 16, 1630-1640.	5.0	129
14	Factor H and Atypical Hemolytic Uremic Syndrome: Mutations in the C-Terminus Cause Structural Changes and Defective Recognition Functions. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 170-177.	3.0	115
15	Factor H: A Complement Regulator in Health and Disease, and a Mediator of Cellular Interactions. <i>Biomolecules</i> , 2012, 2, 46-75.	1.8	115
16	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. <i>American Journal of Pathology</i> , 2005, 167, 1173-1181.	1.9	108
17	Factor H and Factor H-Related Protein 1 Bind to Human Neutrophils via Complement Receptor 3, Mediate Attachment to <i>Candida albicans</i> , and Enhance Neutrophil Antimicrobial Activity. <i>Journal of Immunology</i> , 2010, 184, 912-921.	0.4	107
18	Anti-factor B autoantibody in dense deposit disease. <i>Molecular Immunology</i> , 2010, 47, 1476-1483.	1.0	97

#	ARTICLE	IF	CITATIONS
19	The C-terminus of complement factor H is essential for host cell protection. <i>Molecular Immunology</i> , 2007, 44, 2697-2706.	1.0	95
20	Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes. <i>Journal of Immunology</i> , 2002, 168, 2782-2788.	0.4	85
21	Regulation of regulators: Role of the complement factor H-related proteins. <i>Seminars in Immunology</i> , 2019, 45, 101341.	2.7	82
22	Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 136-144.	0.4	78
23	Factor H-related Protein 4 Activates Complement by Serving as a Platform for the Assembly of Alternative Pathway C3 Convertase via Its Interaction with C3b Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 19528-19536.	1.6	77
24	Autoantibodies in haemolytic uraemic syndrome (HUS). <i>Thrombosis and Haemostasis</i> , 2009, 101, 227-232.	1.8	76
25	Factor H-Related Protein 5 Interacts with Pentraxin 3 and the Extracellular Matrix and Modulates Complement Activation. <i>Journal of Immunology</i> , 2015, 194, 4963-4973.	0.4	75
26	Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. <i>Kidney International</i> , 2011, 80, 397-404.	2.6	70
27	An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H. <i>Journal of Immunology</i> , 2013, 191, 912-921.	0.4	70
28	A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. <i>International Immunology</i> , 1998, 10, 1923-1930.	1.8	69
29	The Major Autoantibody Epitope on Factor H in Atypical Hemolytic Uremic Syndrome Is Structurally Different from Its Homologous Site in Factor H-related Protein 1, Supporting a Novel Model for Induction of Autoimmunity in This Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 9500-9510.	1.6	69
30	Human Pentraxin 3 Binds to the Complement Regulator C4b-Binding Protein. <i>PLoS ONE</i> , 2011, 6, e23991.	1.1	68
31	Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. <i>Histology and Histopathology</i> , 2004, 19, 251-8.	0.5	66
32	Atypical Hemolytic Uremic Syndrome-Associated Variants and Autoantibodies Impair Binding of Factor H and Factor H-Related Protein 1 to Pentraxin 3. <i>Journal of Immunology</i> , 2012, 189, 1858-1867.	0.4	62
33	Factor H Family Proteins in Complement Evasion of Microorganisms. <i>Frontiers in Immunology</i> , 2017, 8, 571.	2.2	60
34	Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 506-514.	3.0	59
35	Pathogenic <i>Leptospira</i> Species Acquire Factor H and Vitronectin via the Surface Protein LcpA. <i>Infection and Immunity</i> , 2015, 83, 888-897.	1.0	57
36	Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells. <i>Molecular Immunology</i> , 2009, 46, 335-344.	1.0	56

#	ARTICLE	IF	CITATIONS
37	Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. <i>Immunology Letters</i> , 2014, 160, 163-171.	1.1	50
38	Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models. <i>Frontiers in Immunology</i> , 2018, 9, 1691.	2.2	50
39	FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene. <i>European Journal of Human Genetics</i> , 2005, 13, 321-329.	1.4	45
40	Autoimmune forms of thrombotic microrangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. <i>Molecular Immunology</i> , 2009, 46, 2801-2807.	1.0	44
41	FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation. <i>Journal of Immunology</i> , 2017, 199, 292-303.	0.4	43
42	Complement Factor H-Antibody-Associated Hemolytic Uremic Syndrome: Pathogenesis, Clinical Presentation, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 431-443.	1.5	41
43	Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family. <i>Frontiers in Immunology</i> , 2018, 9, 1607.	2.2	39
44	Molecular basis of C-reactive protein binding and modulation of complement activation by factor H-related protein 4. <i>Molecular Immunology</i> , 2010, 47, 1347-1355.	1.0	38
45	Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps. <i>Molecular Immunology</i> , 2016, 72, 37-48.	1.0	34
46	Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2016, 70, 47-55.	1.0	33
47	Autoantibodies in haemolytic uraemic syndrome (HUS). <i>Thrombosis and Haemostasis</i> , 2009, 101, 227-32.	1.8	33
48	Secreted aspartic protease 2 of <i>Candida albicans</i> inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18). <i>Immunology Letters</i> , 2015, 168, 13-21.	1.1	32
49	Differential Interaction of the Two Related Fungal Species <i>Candida albicans</i> and <i>Candida dubliniensis</i> with Human Neutrophils. <i>Journal of Immunology</i> , 2012, 189, 2502-2511.	0.4	31
50	Complement factor H family proteins in their non-canonical role as modulators of cellular functions. <i>Seminars in Cell and Developmental Biology</i> , 2019, 85, 122-131.	2.3	30
51	Functional Characterization of Secreted Aspartyl Proteases in <i>Candida parapsilosis</i> . <i>MSphere</i> , 2019, 4, .	1.3	29
52	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. <i>Immunobiology</i> , 2016, 221, 503-511.	0.8	28
53	Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. <i>European Journal of Immunology</i> , 2000, 30, 1706-1713.	1.6	27
54	A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. <i>Frontiers in Immunology</i> , 2021, 12, 660194.	2.2	26

#	ARTICLE	IF	CITATIONS
55	Role of pH-regulated antigen 1 of <i>Candida albicans</i> in the fungal recognition and antifungal response of human neutrophils. <i>Molecular Immunology</i> , 2011, 48, 2135-2143.	1.0	25
56	Two factor H-related proteins from the mouse: expression analysis and functional characterization. <i>Immunogenetics</i> , 2006, 58, 883-893.	1.2	24
57	Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 156.	1.2	24
58	Ecotin, a microbial inhibitor of serine proteases, blocks multiple complement dependent and independent microbicidal activities of human serum. <i>PLoS Pathogens</i> , 2019, 15, e1008232.	2.1	24
59	Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1023-1031.	1.7	22
60	Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization. <i>Frontiers in Immunology</i> , 2020, 11, 1297.	2.2	21
61	Identification of Neuronal Pentraxins as Synaptic Binding Partners of C1q and the Involvement of NP1 in Synaptic Pruning in Adult Mice. <i>Frontiers in Immunology</i> , 2020, 11, 599771.	2.2	21
62	Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 133-136.	1.4	20
63	Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome. <i>Frontiers in Immunology</i> , 2017, 8, 302.	2.2	18
64	Factor H-Related Proteins. <i>Methods in Molecular Biology</i> , 2014, 1100, 225-236.	0.4	17
65	Complement Factor H-Related Protein 4A Is the Dominant Circulating Splice Variant of CFHR4. <i>Frontiers in Immunology</i> , 2018, 9, 729.	2.2	15
66	Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. <i>Frontiers in Immunology</i> , 2021, 12, 642860.	2.2	15
67	FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells. <i>Molecular Oncology</i> , 2019, 13, 2531-2553.	2.1	14
68	The Murine Factor H-Related Protein FHR-B Promotes Complement Activation. <i>Frontiers in Immunology</i> , 2017, 8, 1145.	2.2	13
69	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. <i>Frontiers in Immunology</i> , 2021, 12, 720183.	2.2	12
70	Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation. <i>Frontiers in Immunology</i> , 2022, 13, 845953.	2.2	11
71	Genetic screening in haemolytic uraemic syndrome. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 653-657.	1.0	10
72	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660382.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H. <i>Antibodies</i> , 2018, 7, 14.	1.2	6
74	Editorial: Function and Dysfunction of Complement Factor H. <i>Frontiers in Immunology</i> , 2021, 12, 831044.	2.2	6
75	Complement Factor H Family Proteins Modulate Monocyte and Neutrophil Granulocyte Functions. <i>Frontiers in Immunology</i> , 2021, 12, 660852.	2.2	5
76	Role of complement and Factor H in hemolytic uremic syndrome. , 2006, , 85-109.		4
77	The possible role of factor H in complement activation-related pseudoallergy (CARPA): a failed attempt to correlate blood levels of FH with liposome-induced hypersensitivity reactions in patients with autoimmune disease. <i>European Journal of Nanomedicine</i> , 2015, 7, .	0.6	4
78	Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. <i>Frontiers in Immunology</i> , 2017, 8, 1800.	2.2	4
79	Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. <i>Frontiers in Immunology</i> , 2019, 10, 240.	2.2	4
80	Detection of Complement Factor B Autoantibodies by ELISA. <i>Methods in Molecular Biology</i> , 2021, 2227, 141-145.	0.4	3
81	Pathogenic D76N Variant of β_2 -Microglobulin: Synergy of Diverse Effects in Both the Native and Amyloid States. <i>Biology</i> , 2021, 10, 1197.	1.3	3
82	Characterization of factor H-related cell membrane molecules expressed by human B lymphocytes and neutrophil granulocytes. <i>Immunology Letters</i> , 2001, 77, 55-62.	1.1	2
83	Interaction of the long pentraxin PTX3 with soluble complement inhibitors. <i>Molecular Immunology</i> , 2010, 47, 2234-2235.	1.0	1
84	Anti-Complement Autoantibodies in Membranoproliferative Glomerulonephritis and Dense Deposit Disease. , 2011, , .		1
85	Elevated pentraxin-3 is associated with alternative pathway dysregulation in the acute phase of thrombotic microangiopathies. <i>Molecular Immunology</i> , 2018, 102, 222-223.	1.0	1
86	Regulation of B-cell activation by complement receptors CR1 (CD35) and CR2 (CD21) – possible involvement in the pathogenesis of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2004, 3, 624-625.	2.5	0
87	Functional characterization of a disease-associated N-terminal factor H mutation. <i>Immunobiology</i> , 2016, 221, 1176.	0.8	0
88	Interaction of factor H family proteins with DNA and dead cells: Implications for the regulation of opsonization. <i>Molecular Immunology</i> , 2017, 89, 140-141.	1.0	0
89	Relationship between CFHR5 and complement parameters in patients suffering from complement-mediated kidney disorders, with or without CFHR5 mutations. <i>Molecular Immunology</i> , 2017, 89, 177.	1.0	0
90	Assessment of the C3b- and iC3b-binding ability of CFHR5 variants. <i>Molecular Immunology</i> , 2018, 102, 141.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Screening for anti-factor B autoantibody in a patient with acute renal injury due to dense deposit disease. <i>Clinical Nephrology</i> , 2012, 77, 85-86.	0.4	0
92	A Case of CFH-Ab Hus Responsive to Plasmapheresis and with Sustained Remission after Initiation of Immunosuppressive Therapy Highlighting the Common Pit Falls of a Complicated Disease. <i>Journal of Clinical & Experimental Nephrology</i> , 2016, 01, .	0.1	0